XLXinyang Li

Xinyang Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xinyang Li has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Qing Liu

    Department of Epidemiology, School of Public Health, Wuhan University, Wuhan 430071, China

    1 shared publication
  • Ting Luo

    Affiliation School of Stomatology, Wuhan University, Wuhan, Hubei, China

    1 shared publication
  • Xian-Tao Zeng

    Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University

    1 shared publication
  • Xianrui Zhong

    Affiliation Department of Computer Science, University of Illinois at Urbana-Champaign, Champaign, Illinois, United States of America

    1 shared publication
  • Yongbo Wang

    Affiliation Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China

    1 shared publication

Latest Publications

  • Top Cited Papers
    Open Access

    Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis

    by Xinyang Li, Xianrui Zhong, Yongbo Wang, Xiantao Zeng, Ting Luo, Qing Liu

    Objective: We aimed to systematically identify the possible risk factors responsible for severe cases.Methods: We searched PubMed, Embase, Web of science and Cochrane Library for epidemiological studies of confirmed COVID-19, which include information about clinical characteristics and severity of patients’ disease. We analyzed the potential associations between clinical characteristics and severe cases.Results: We identified a total of 41 eligible studies including 21060 patients with COVID-19. Severe cases were potentially associated with advanced age (Standard Mean Difference (SMD) = 1.73, 95% CI: 1.34–2.12), male gender (Odds Ratio (OR) = 1.51, 95% CI:1.33–1.71), obesity (OR = 1.89, 95% CI: 1.44–2.46), history of smoking (OR = 1.40, 95% CI:1.06–1.85), hypertension (OR = 2.42, 95% CI: 2.03–2.88), diabetes (OR = 2.40, 95% CI: 1.98–2.91), coronary heart disease (OR: 2.87, 95% CI: 2.22–3.71), chronic kidney disease (CKD) (OR = 2.97, 95% CI: 1.63–5.41), cerebrovascular disease(OR = 2.47, 95% CI: 1.54–3.97), chronic obstructive pulmonary disease (COPD) (OR = 2.88, 95% CI: 1.89–4.38), malignancy (OR = 2.60, 95% CI: 2.00–3.40), and chronic liver disease (OR = 1.51, 95% CI: 1.06–2.17). Acute respiratory distress syndrome (ARDS) (OR = 39.59, 95% CI: 19.99–78.41), shock (OR = 21.50, 95% CI: 10.49–44.06) and acute kidney injury (AKI) (OR = 8.84, 95% CI: 4.34–18.00) were most likely to prevent recovery. In summary, patients with severe conditions had a higher rate of comorbidities and complications than patients with non-severe conditions.Conclusion: Patients who were male, with advanced age, obesity, a history of smoking, hypertension, diabetes, malignancy, coronary heart disease, hypertension, chronic liver disease, COPD, or CKD are more likely to develop severe COVID-19 symptoms. ARDS, shock and AKI were thought to be the main hinderances to recovery.